

### **AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions, and listings, of claims in this application.

1. **(Currently Amended)** A method of treating an inflammatory disorder in a patient comprising

administering to a patient suffering from an inflammatory disorder at least one treatment selected from the group consisting of: inducing ferritin in the patient; expressing ferritin in the patient; and administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one of heme oxygenase-1 (HO-1), bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin to the patient, in an amount sufficient to treat the inflammatory disorder;

wherein the inflammatory disorder is localized in the gastrointestinal tract ~~selected from the group consisting of asthma, adult respiratory distress syndrome, interstitial pulmonary fibrosis, pulmonary emboli, chronic obstructive pulmonary disease, primary pulmonary hypertension, chronic pulmonary emphysema, congestive heart failure, peripheral vascular disease, stroke, heart attacks, glomerulonephritis, conditions involving inflammation of the kidney, lung, liver, spleen, brain and/or skin, infection of the genitourinary tract, viral and toxic hepatitis, cirrhosis, ileus, necrotizing enterocolitis, specific and non-specific inflammatory bowel disease, rheumatoid arthritis, deficient wound healing, Alzheimer's disease, Parkinson's disease, graft versus host disease, hemorrhagic, septic, or anaphylactic shock, amoebic dysentery, bacillary dysentery, schistosomiasis, campylobacter enterocolitis, yersinia enterocolitis, enterobius vermicularis, radiation enterocolitis, ischaemic colitis, eosinophilic gastroenteritis, ulcerative colitis, indeterminate colitis, Crohn's disease and an inflammatory condition localized in the gastrointestinal tract.~~

2. **(Original)** The method of claim 1, wherein the treatment is inducing ferritin in the patient.

3. **(Original)** The method of claim 1, wherein the treatment is expressing ferritin in the patient.

4. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising HO-1 to the patient.

5. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising biliverdin to the patient.

6. **(Original)** The method of claim 5, wherein the pharmaceutical composition is administered to the patient at a dosage of about 1 to 1000 micromoles/kg/day.

7. **(Currently Amended)** The method of claim [[6]]1, wherein the inflammatory disorder is ulcerative colitis.

8. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising bilirubin to the patient.

9. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising ferritin to the patient.

10. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising desferoxamine (DFO) or salicylaldehyde isonicotinoyl hydrazone (SIH) to the patient.

11. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising iron dextran to the patient.

12. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising apoferritin to the patient.

13. **(Original)** The method of claim 2, wherein the ferritin is induced by administering iron to the patient.

14-16. **(Cancelled)**

17. **(Previously Presented)** The method of claim 1, wherein the inflammatory disorder is selected from the group consisting of: amoebic dysentery, bacillary dysentery, schistosomiasis, campylobacter enterocolitis, yersinia enterocolitis, enterobius vermicularis,

radiation enterocolitis, ischaemic colitis, eosinophilic gastroenteritis, ulcerative colitis, indeterminate colitis, and Crohn's disease.

18. **(Previously Presented)** The method of claim 1, wherein the inflammatory disorder is ulcerative colitis.

19. **(Original)** The method of claim 1, further comprising the step of administering to the patient at least one treatment selected from the group consisting of: inducing HO-1 in the patient; expressing HO-1 in the patient; and administering a pharmaceutical composition comprising carbon monoxide to the patient.

20. **(Previously Presented)** The method of claim 1, further comprising the steps of inducing HO-1 in the patient, and administering a pharmaceutical composition comprising carbon monoxide to the patient.

21-62. **(Cancelled)**